Us chamber comments on eu pharmaceutical strategy final sept 2020
Published
September 15, 2020
This submission complements the Chamber’s ongoing support for the Commission’s work to remove trade barriers and to protect intellectual property (IP) in the European Union (EU) and internationally .
The Chamber respectfully offers several suggestions for how Europe can begin to reclaim a leadership role and become a more attractive investment destination for biopharmaceuticals and ensure Europeans can access the very latest innovative medicines.
